Makoto Braxton

Makoto Braxton serves as a key procurement lead within the Administration for Strategic Preparedness and Response (ASPR), where they oversee the acquisition of critical biomedical and manufacturing capabilities essential to national health security. Responsible for executing contracts that support the rapid development, scaling, and deployment of medical countermeasures, Braxton plays a central role in sustaining the nation’s biomedical industrial base. Their portfolio primarily includes high-priority procurements for pharmaceutical preparations and plastic resin-based medical supply systems, ensuring alignment with ASPR’s mission of emergency readiness and supply chain resilience. These acquisitions are strategically timed to support surge capacity during public health emergencies, including pandemics and chemical-biological incidents. Braxton maintains a broad network of industrial suppliers across the pharmaceutical and plastics manufacturing sectors, engaging both large-scale producers and specialized contract manufacturers with GMP and FDA-compliant capabilities. While no single contractor dominates their award profile, their contracting patterns reflect a preference for vendors with proven expertise in sterile manufacturing, lyophilization, and medical-grade polymer extrusion. Relationships are characterized by long-term strategic partnerships, often involving multi-year indefinite-delivery/indefinite-quantity (IDIQ) vehicles and urgent requirement mechanisms such as Other Transaction Authority (OTA) or emergency procurement authorities under the Defense Production Act. Braxton’s contracting activity shows no preference for socioeconomic set-asides, with 100% of awards issued under full and open competition. This reflects a mission-driven prioritization of speed, scalability, and technical capability over socioeconomic criteria during acute preparedness cycles. While small business participation is not formally incentivized in their portfolio, vendors of all sizes are evaluated strictly on technical merit, production capacity, and supply chain reliability. Their core procurement focus centers on NAICS 325412 (Pharmaceutical Preparation Manufacturing) and 325211 (Plastics Material and Resin Manufacturing), underscoring deep expertise in sterile injectables, vaccine delivery systems, syringe components, and single-use medical devices. Braxton’s technical domain knowledge spans cGMP compliance, cold chain logistics, and polymer science, enabling informed decisions on complex biomedical supply chain requirements.